Home > Insider Trading > Filing (0000899243-21-050130)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	A6

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1164475	J Ronald Daniels	C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-12-28	11,745	$12.73	11,745	No	4	P	Direct
Common Stock	Disposition	2021-12-28	11,745	$12.80	0	No	4	S	Direct
Common Stock	Acquisiton	2021-12-30	10,402	$14.34	10,402	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	S	Direct
No	4	P	Direct

Footnotes

The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions.
Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3.
Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share.